{"qas": [{"question": "What is subject to the Orphan Drug Act?", "id": "571af9329499d21900609bc5", "answers": [{"text": "diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances", "answer_start": 129}], "is_impossible": false}, {"question": "What is given to companies who develop drugs for \"orphan diseases\"?", "id": "571af9329499d21900609bc6", "answers": [{"text": "tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents", "answer_start": 426}], "is_impossible": false}, {"question": "Why are these companies rewarded?", "id": "571af9329499d21900609bc7", "answers": [{"text": "Because medical research and development of drugs to treat such diseases is financially disadvantageous", "answer_start": 282}], "is_impossible": false}, {"question": "What is a term for rare diseases in some territories?", "id": "571d2b4ddd7acb1400e4c234", "answers": [{"text": "orphan diseases", "answer_start": 52}], "is_impossible": false}, {"question": "What size of disease populations are subject to the Orphan Drug Act?", "id": "571d2b4ddd7acb1400e4c235", "answers": [{"text": "fewer than 200,000 patients", "answer_start": 148}], "is_impossible": false}, {"question": "What is one financial benefit to researching orphan drugs?", "id": "571d2b4ddd7acb1400e4c236", "answers": [{"text": "tax reductions", "answer_start": 426}], "is_impossible": false}, {"question": "What is the length of time of market exclusivity of an orphan drug?", "id": "571d2b4ddd7acb1400e4c237", "answers": [{"text": "seven years", "answer_start": 511}], "is_impossible": false}, {"plausible_answers": [{"text": "diseases involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances", "answer_start": 129}], "question": "What is subject to patients in the United States?", "id": "5ad3a4c6604f3c001a3fea95", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents", "answer_start": 426}], "question": "What is given to companies who develop rules for \"orphan diseases\"?", "id": "5ad3a4c6604f3c001a3fea96", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Because medical research and development of drugs to treat such diseases is financially disadvantageous", "answer_start": 282}], "question": "Why are these rules rewarded?", "id": "5ad3a4c6604f3c001a3fea97", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "orphan diseases", "answer_start": 52}], "question": "What is a term for rare rules in some territories?", "id": "5ad3a4c6604f3c001a3fea98", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "fewer than 200,000 patients", "answer_start": 148}], "question": "What size of disease populations are subject to patents?", "id": "5ad3a4c6604f3c001a3fea99", "answers": [], "is_impossible": true}], "context": "There are special rules for certain rare diseases (\"<a3_0><b10_0>orphan diseases<b10_0/><a3_0/>\") in several major drug regulatory territories. For example, <a0_0><b7_0>diseases involving <a4_0><b11_0>fewer than 200,000 patients<b11_0/><a4_0/> in the United States, or larger populations in certain circumstances<b7_0/><a0_0/> are subject to the Orphan Drug Act.  <a2_0><b9_0>Because medical research and development of drugs to treat such diseases is financially disadvantageous<b9_0/><a2_0/>, companies that do so are rewarded with <a1_0><a5_0><b8_0>tax reductions<a5_0/>, fee waivers, and market exclusivity on that drug for a limited time (<a6_0>seven years<a6_0/>), regardless of whether the drug is protected by patents<b8_0/><a1_0/>."}